Cargando…

Booster dose of BNT162b2 after two doses of CoronaVac improves neutralization of SARS-CoV-2 Omicron variant

BACKGROUND: The emergence of the new SARS-CoV-2 Omicron variant, which is known to have a large number of mutations when compared to other variants, brought to light the concern about vaccine escape, especially from the neutralization by antibodies induced by vaccination. METHODS: Based on viral mic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Campos, Guilherme R. F., Almeida, Nathalie Bonatti Franco, Filgueiras, Priscilla Soares, Corsini, Camila Amormino, Gomes, Sarah Vieira Contin, de Miranda, Daniel Alvim Pena, de Assis, Jéssica Vieira, de Souza Silva, Thaís Bárbara, Alves, Pedro Augusto, da Rocha Fernandes, Gabriel, de Oliveira, Jaquelline Germano, Rahal, Paula, Grenfell, Rafaella Fortini Queiroz, Nogueira, Maurício L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242982/ https://www.ncbi.nlm.nih.gov/pubmed/35784447 http://dx.doi.org/10.1038/s43856-022-00141-4

Ejemplares similares

Booster dose of BNT162b2 in a CoronaVac primary vaccination protocol improves neutralization of SARS-CoV-2 Omicron variant
por: Campos, Guilherme R. F., et al.
Publicado: (2022)

CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

A Randomized Clinical Trial Using CoronaVac or BNT162b2 Vaccine as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac
por: Mok, Chris Ka Pun, et al.
Publicado: (2022)

Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study
por: Grenfell, Rafaella F. Q., et al.
Publicado: (2022)

Reply to Mungmunpuntipantip and Wiwanitkit: CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mok, Chris Ka Pun, et al.
Publicado: (2022)

BNT162b2 or CoronaVac as the Third Dose against Omicron: Neutralizing Antibody Responses among Transplant Recipients Who Had Received Two Doses of CoronaVac
por: Erol, Çiğdem, et al.
Publicado: (2023)

Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine
por: Fonseca, Marcela Helena Gambim, et al.
Publicado: (2022)

Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2022)

Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity
por: Leung, Daniel, et al.
Publicado: (2022)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
por: Çulpan, Hazal Cansu, et al.
Publicado: (2023)

Relative Vaccine Effectiveness of the Third Dose of CoronaVac or BNT162b2 Following a Two-Dose CoronaVac Regimen: A Prospective Observational Cohort Study from an Adult Vaccine Center in Turkey
por: Sonmezer, Meliha Cagla, et al.
Publicado: (2022)

Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial
por: Samoud, Samar, et al.
Publicado: (2023)

Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2022)

Humoral and cellular responses to vaccination with homologous CoronaVac or ChAdOx1 and heterologous third dose with BNT162b2
por: Hayashi, Jackelinne Y., et al.
Publicado: (2022)

Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID‐19 vaccines in Hong Kong
por: Mok, Chris Ka Pun, et al.
Publicado: (2021)

Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study
por: Kang, Wei, et al.
Publicado: (2022)

Rapid antigen test as a tool for the identification of SARS-CoV-2 infection and its potential as a self-testing device
por: Filgueiras, Priscilla Soares, et al.
Publicado: (2023)

Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines
por: Zhang, Ruiqi, et al.
Publicado: (2022)

Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study
por: Suah, Jing Lian, et al.
Publicado: (2022)

Side Effects Related to BNT162b2 and CoronaVac Vaccine Requiring Emergency Department Visit
por: Yavuz, Erdal, et al.
Publicado: (2022)

Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2
por: Rammauro, Florencia, et al.
Publicado: (2022)

Heterologous Booster with BNT162b2 Induced High Specific Antibody Levels in CoronaVac Vaccinees
por: Masson, Letícia Carrijo, et al.
Publicado: (2023)

Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
por: Rosa Duque, Jaime S., et al.
Publicado: (2022)

Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines
por: Zhang, Xiaojuan, et al.
Publicado: (2023)

Effectiveness of BNT162b2 and CoronaVac vaccines against omicron in children aged 5 to 11 years
por: Oliveira, Eduardo A., et al.
Publicado: (2023)

Safety and Immunogenicity of a Booster Vaccination by CoronaVac or BNT162b2 in Previously Two-Dose Inactivated Virus Vaccinated Individuals with Negative Neutralizing Antibody
por: Lai, Kristi Tsz-Wan, et al.
Publicado: (2022)

Tuberculosis following two-dose SARS-CoV-2 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac)
por: Li, Xue, et al.
Publicado: (2023)

Leukocytoclastic vasculitis after the third dose of CoronaVac vaccination
por: Oskay, T., et al.
Publicado: (2021)

Effectiveness of CoronaVac and BNT162b2 COVID-19 mass vaccination in Colombia: A population-based cohort study
por: Paternina-Caicedo, Angel, et al.
Publicado: (2022)

Effectiveness of BNT162b2 booster after CoronaVac primary regimen in pregnant people during omicron period in Brazil
por: Florentino, Pilar T V, et al.
Publicado: (2022)

Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study
por: McMenamin, Martina E, et al.
Publicado: (2022)

Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant
por: Khong, Ka-Wa, et al.
Publicado: (2022)

Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients
por: Cheung, Ka Shing, et al.
Publicado: (2022)

Humoral Immune Response of BNT162b2 and CoronaVac Vaccinations in Hemodialysis Patients: A Multicenter Prospective Cohort
por: Clavero, Rene, et al.
Publicado: (2022)

Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University
por: Makanut, Supawadee, et al.
Publicado: (2023)

Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants
por: Niyomnaitham, Suvimol, et al.
Publicado: (2023)

Evaluation of schistosomula crude antigen (SCA) as a diagnostic tool for Schistosoma mansoni in low endemic human population
por: Oyeyemi, Oyetunde Timothy, et al.
Publicado: (2021)

Safety and immunogenicity of intradermal administration of fractional dose CoronaVac(®), ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination
por: Chatsiricharoenkul, Somruedee, et al.
Publicado: (2022)

Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case–control study
por: Yan, Vincent Ka Chun, et al.
Publicado: (2023)

Author Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
por: Rosa Duque, Jaime S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lv85smtp5e6ddiraafrrlm4t2u